Standardization of chemotherapy and individual dosing of platinum compounds

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 465-470

  Puisset, Florent ^a   Schmitt, Antonin ^b   Chatelut, Etienne ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Chemotherapy; Dosing; Platinum; Review

Indexed keywords

CARBOPLATIN; CISPLATIN; PLATINUM; PLATINUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BODY SURFACE; CANCER CHEMOTHERAPY; CONFERENCE PAPER; DNA ADDUCT; DRUG ABSORPTION; DRUG HALF LIFE; GLOMERULUS FILTRATION RATE; HUMAN; INTRINSIC ACTIVITY; KIDNEY TUBULE ABSORPTION; PLASMA PROTEIN BINDING; PREDICTION; PROSPECTIVE STUDY; CHEMOTHERAPY; DOSE RESPONSE; DOSING; NEOPLASM; PATIENT CARE; PERSONALIZED MEDICINE; REVIEW; STANDARD;

CHEMOTHERAPY; DOSING; PLATINUM; REVIEW;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PATIENT-CENTERED CARE; REFERENCE STANDARDS;

EID: 84897025902     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Pinkel D: The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 18(7): 853-856, 1958.
2. Freireich EJ, Gehan EA, Rall DP, Schmidt LH and Skipper HE: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50(4): 219-244, 1966.
3. Yonezawa A, Masuda S, Yokoo S, Katsura T and Inui K: Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 319(2): 879-886, 2006.
4. Elferink F, van der Vijgh WJ, Klein I, Vermorken JB, Gall HE and Pinedo HM: Pharmacokinetics of carboplatin after i.v. administration. Cancer Treat Rep 71(12): 1231-1237, 1987.
5. van der Vijgh WJ: Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21(4): 242-261, 1991.
6. Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A and Aisner J: Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res 45(12 Pt 1): 6502-6506, 1985.
7. Lokich J and Anderson N: Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 9(1): 13-21, 1998.
8. Benezet S, Guimbaud R, Chatelut E, Chevreau C, Pujol A, Boneu A, Roche H, Houin G and Bugat R: How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients. Ann Oncol 8(6): 607-609, 1997.
9. Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, Roche H, Houin G and Bugat R: Prediction of carboplatin clearance from morphological and biological patient characteristics 87(8): 573-580, 1995.
10. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW and Aisner J: Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res 44(11): 5432-5438 1984.
11. Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le GC, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I and Chatelut E: A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res 15(10): 3633-3639, 2009.
12. Thomas F, Seronie-Vivien S, Gladieff L, Dalenc F, Durrand V, Malard L, Lafont T, Poublanc M, Bugat R and Chatelut E: Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin. Clin Pharmacokinet 44(12): 1305-1316, 2005.
13. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME and Wiltshaw E: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7(11): 1748-1756, 1989.
14. Leger F, Seronie-Vivien S, Makdessi J, Lochon I, Delord JP, Sarda C, Canal P and Chatelut E: Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: a prospective study. Eur J Cancer 38(1): 52-56, 2002.
15. Newman DJ: Cystatin C. Ann Clin Biochem 39(Pt 2): 89-104, 2002.
16. Belani CP, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, Engstrom C, Ramanathan RK, Capozzoli MJ, Aisner J and Egorin MJ: Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 17(2): 676-684, 1999.
17. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S and Wiltshaw E: Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10(4): 520-528, 1992.
18. Belani CP, Egorin MJ, Abrams JS, Hiponia D, Eisenberger M, Aisner J and Van Echo DA: A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide. J Clin Oncol 7(12): 1896-1902, 1989.
19. Schmitt A, Gladieff L, Laffont CM, Evrard A, Boyer JC, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Mousseau M, Pinguet F, Floquet A, Billaud EM, Durdux C, Le GC, Mazieres J, Lafont T, Ollivier F, Concordet D and Chatelut E: Factors for hematopoietic toxicity of carboplatin: Refining the targeting of carboplatin systemic exposure. J Clin Oncol 20;28(30): 4568-74, 2010.
20. Bajorin DF, Bosl GJ, Alcock NW, Niedzwiecki D, Gallina E and Shurgot B: Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline. Cancer Res 46(11): 5969-5972, 1986.
21. Schellens JH, Ma J, Planting AS, van der Burg ME, van ME, de Boer-Dennert M, Schmitz PI, Stoter G and Verweij J: Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 73(12): 1569-1575, 1996.
22. Urien S and Lokiec F: Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 57(6): 756-763, 2004.
23. de Jongh FE, Verweij J, Loos WJ, de WR, de Jonge MJ, Planting AS, Nooter K, Stoter G and Sparreboom A: Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 19(17): 3733-9, 2001.
24. de Jongh FE, Gallo JM, Shen M, Verweij J and Sparreboom A: Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother Pharmacol 54(2): 105-112, 2004.
25. Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J and Baker SD: Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 20;25(30): 4707-4713, 2007.
26. Loos WJ, de Jongh FE, Sparreboom A, de WR, van Boven-van Zomeren DM, Stoter G, Nooter K and Verweij J: Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol 24(10): 1499-1506, 2006.
27. Chatelut E, White-Koning ML, Mathijssen RH, Puisset F, Baker SD and Sparreboom A: Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer 107(7): 1100-1106, 2012.